SCHEMBL2595802

SCHEMBL2595802

CS(=O)(=O)c1ccc2nccc(Nc3n[nH]c4ccc(Cl)cc34)c2c1

nearest known ligand 0.78

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RIPK2 O43353 13/20 0.78
KCNH2 Q12809 7/20 0.62
GAK O14976 3/20 0.62
MAPK14 Q16539 2/20 0.62
LCK P06239 1/20 0.62
TGFBR1 P36897 1/20 0.62
RIPK3 Q9Y572 1/20 0.62
KDR P35968 2/20 0.50
RET P07949 1/20 0.50
PKMYT1 Q99640 1/20 0.50
RAF1 P04049 2/20 0.49
BRAF P15056 2/20 0.49
CA9 Q16790 1/20 0.47
FADS1 O60427 1/20 0.45
COQ8A Q8NI60 1/20 0.43
NLK Q9UBE8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2589223 0.92 RIPK2 (0.68) RIPK2KCNH2GAKMAPK14LCK
SCHEMBL2595620 0.88 RIPK2 (1.00) RIPK2KCNH2GAKMAPK14LCK
SCHEMBL2596154 0.86 RIPK2 (0.75) RIPK2KCNH2GAKMAPK14LCK
SCHEMBL17552302 0.82 RIPK2 (0.70) RIPK2KCNH2GAKMAPK14LCK
SCHEMBL2596066 0.82 RIPK2 (0.63) RIPK2KCNH2GAKMAPK14LCK
SCHEMBL2591694 0.79 RIPK2 (0.60) RIPK2KCNH2GAKMAPK14TGFBR1
SCHEMBL2596055 0.79 RIPK2 (0.69) RIPK2KCNH2GAKMAPK14TGFBR1
SCHEMBL12180625 0.78 RIPK2 (0.64) RIPK2KCNH2GAKMAPK14LCK
SCHEMBL2588825 0.77 RIPK2 (0.64) RIPK2KCNH2GAKMAPK14TGFBR1
SCHEMBL2595766 0.77 RIPK2 (1.00) RIPK2KCNH2GAKMAPK14LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2566477-B1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2015-09-02 EP claimed
US-20130053375-A1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXO GROUP LIMITED 2013-02-28 US claimed
US-20160060222-A1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXOSMITHKLINE LLC 2016-03-03 US disclosed
US-20160060222-A1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXOSMITHKLINE LLC 2016-03-03 US disclosed
EP-2566477-B1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2015-09-02 EP disclosed
EP-2566477-A1 AMINO-QUINOLINES AS KINASE INHIBITORS Glaxo Group Limited (GB) 2013-03-13 EP disclosed
US-20130053375-A1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXO GROUP LIMITED 2013-02-28 US disclosed
US-20130053375-A1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXO GROUP LIMITED 2013-02-28 US disclosed
WO-2011140442-A1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2011-11-10 WO disclosed
WO-2011140442-A1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2011-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160060222-A1 AMINO-QUINOLINES AS KINASE INHIBITORS ABL1, MAP3K2, MAP4K2 RIPK2 326/4885KCNH2 1159/4885GAK 162/4885
US-20130053375-A1 AMINO-QUINOLINES AS KINASE INHIBITORS ABL1, MAP3K2, MAP4K2 RIPK2 326/4885KCNH2 1159/4885GAK 162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.